This suggests that non-V600 BRAF mutations may be sufficient to initiate cancer but may require further alterations in the RAS pathway for tumor progression, as non-V600 mutations are not as potent in activating the RAS pathway as V600 mutation in BRAF [15]. The gene discussed is BRAF; the disease is neoplasm.